Last Patient Dosed in Phase 2a Alzheimer’s Study
Neurotrope, Inc. announced that the last patient has been dosed in its Phase 2a clinical trial of Bryostatin-1 for the treatment of patients with Alzheimer's disease (AD). The trial is being conducted under an Investigational New Drug (IND) applicat ...